Eisai Company, Ltd. Puts $200 Million into US Personalised Medicine Unit
Published: Jan 31, 2011
Pharma Times -- Eisai has formed a biotech start-up in the USA, H3 Biomedecines, which will focus on discovering and developing next-generation cancer drugs.